Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel
Aapro, Matti S
Beretta, Giordano Domenico
Del Mastro, Lucia
Di Maio, Massimo
De Petris, Luigi
De Marinis, Filippo
AffiliationDivision of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy. firstname.lastname@example.org
MetadataShow full item record
AbstractFebrile neutropenia is a relatively frequent event in cancer patients treated with chemotherapy. A relevant body of scientific evidence has been produced in the last 2 decades, through clinical trials addressing the efficacy of colony stimulating factors (CSFs) in the prevention and treatment of febrile neutropenia. The correct use of CSFs needs to be optimized, and several guidelines have been produced and periodically updated, in order to uniform and guide clinical practice. The aim of this review is to synthesize the most relevant clinical trials and the most important existing guidelines about the role of CSFs in solid tumours. Role of CSFs as primary prophylaxis, secondary prophylaxis and treatment of afebrile and febrile neutropenia is discussed. A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer.
CitationRole of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. 2007, 63 (1):53-64 Crit. Rev. Oncol. Hematol.
JournalCritical Reviews in Oncology/Hematology